Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 239 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Buffered Saline Clear all

Conditions: Normal Healthy Volunteers Will be Treated With Lofexidine to Understand the Absolute Bioavailability and Mass Balance Recovery of the Product
Interventions: Lofexidine hydrochloride; Drug
Lead sponsor: USWM, LLC (dba US WorldMeds); Industry
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Knee Osteoarthritis
Interventions: Euflexxa, Magnetic Resonance Imaging (MRI); Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Zika Virus, Zika Virus Infection
Interventions: VLA1601, Placebo; Biological
Lead sponsor: Valneva Austria GmbH; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Covid19, SARS-CoV Infection
Interventions: Shampoo and saline, Saline and Listerine, Shampoo and Listerine, Saline and Saline; Combination Product
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Hershey, Pennsylvania • State College, Pennsylvania

Conditions: Vancomycin-Resistant Enterococcal Colonization
Interventions: VRELysin™, Placebo; Biological · Other
Lead sponsor: Intralytix, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Respiratory Syncytial Virus Infections
Interventions: MVA BN RSV, Placebo; Biological · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Shigella
Interventions: CVD 1208S, a Shigella flexneri 2a live, oral vaccine, Placebo; Biological · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Osteoarthritis of the Knee
Interventions: Gel-200, Placebo; Device
Lead sponsor: Seikagaku Corporation; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Plantation, Florida

Conditions: Avian Influenza, Influenza Immunisation
Interventions: AS03, Inactivated influenza H7N9 vaccine, Phosphate Buffered Saline (PBS) diluent; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 99 Years
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 2 more

Conditions: Pain During Saline Infusion Sonogram
Interventions: Lidocaine, Sham paracervical block; Drug · Procedure
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Hartsdale, New York

Conditions: Metastatic Melanoma
Interventions: VCL-IM01 (encoding IL-2) with Electroporation; Genetic
Lead sponsor: Vical; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 4
States / cities: Mobile, Alabama • Denver, Colorado • Chicago, Illinois + 1 more

Conditions: Hepatitis C
Interventions: HCV E1E2/MF59, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza
Interventions: Placebo, Trivalent Inactivated Influenza; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Infectious Disease
Interventions: Nozin® Nasal Sanitizer®, Placebo; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: HIV Infections
Interventions: VRC01, SC placebo for VRC01, IV placebo for VRC01; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Cleveland, Ohio + 1 more

Conditions: Critical Limb Ischemia
Interventions: Cord blood stem cell injection; Biological
Lead sponsor: Richard Burt, MD; Other
Eligibility: 18 Years to 72 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Staphylococcal Sepsis
Interventions: Placebo, Pagibaximab 50 mg/mL; Drug
Lead sponsor: Biosynexus Incorporated; Industry
Eligibility: Up to 48 Hours
Enrollment: 1,579 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Gaithersburg, Maryland

Conditions: Osteoarthritis, Knee
Interventions: Zilretta, Synvisc-One 48 MG in 6 ML Prefilled Syringe, Monovisc 88 MG Per 4 ML Prefilled Syringe; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 25 Years to 85 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Columbus, Ohio • Lewis Center, Ohio

Conditions: Lumbar Puncture, Topical Analgesia
Interventions: J-Tip, EMLA, Lidocaine; Device · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 18 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: Pembrolizumab, Flt3L, Radiation, Poly ICLC; Drug · Radiation
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Posttraumatic Stress Disorder (PTSD)
Interventions: Typhoid VI Polysaccharide Vaccine Injectable Solution, Saline Placebo (0.5mL injection); Biological · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cystic Fibrosis
Interventions: GS-5737, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Alzheimer's Disease
Interventions: ACC-001 (vanutide cridificar); Biological
Lead sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Sun City, Arizona • La Jolla, California • Long Beach, California + 20 more

Conditions: Breast Cancer
Interventions: Ad5CMV-p53 gene, chemotherapy; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Lofexidine ADME & Mass Balance in Volunteers

To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial

Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa

Gel-200 Versus Placebo in Osteoarthritis of the Knee

Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

Paracervical Block for Pain Reduction in Saline Infusion Sonograms

A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma

Chiron Corp HCV E1/E2 Vaccine

Th1 Response to Influenza: Aging and Vaccine Efficacy

Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic

Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults

Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia

Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis

Trial Comparing Three Single Dose Injections for Knee Osteoarthritis

Jet Injection of 1% Buffered Lidocaine Versus Topical EMLA for Local Anesthesia Before Lumbar Puncture in Children

Vaccination With Flt3L, Radiation, and Poly-ICLC

Inflammatory Challenge and Fear

Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease

Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer